Free tool
FAERS Monitor: Leukeran
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 010669 or its brand name (Leukeran, Chlorambucil). Reports on generic versions are filed under their own applications.
Reports
3,931
Serious
3,662
93% of reports
Hospitalization
1,632
Death reported
929
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neutropenia279
- pneumonia272
- off label use269
- pyrexia243
- drug ineffective204
- thrombocytopenia199
- anaemia164
- febrile neutropenia162
- disease progression156
- acute myeloid leukaemia131
- infection126
- dyspnoea125
- death116
- nausea112
- progressive multifocal leukoencephalopathy111
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 47 |
| 2005 | 53 |
| 2006 | 35 |
| 2007 | 38 |
| 2008 | 71 |
| 2009 | 72 |
| 2010 | 127 |
| 2011 | 190 |
| 2012 | 215 |
| 2013 | 160 |
| 2014 | 212 |
| 2015 | 207 |
| 2016 | 294 |
| 2017 | 281 |
| 2018 | 457 |
| 2019 | 352 |
| 2020 | 267 |
| 2021 | 224 |
| 2022 | 178 |
| 2023 | 152 |
| 2024 | 134 |
| 2025 | 103 |
| 2026 | 62 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,228 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| progressive multifocal leukoencephalopathySignal | 111 | 73.0 | 60.7 | 7,707 |
| acute myeloid leukaemiaSignal | 131 | 45.3 | 38.3 | 5,594 |
| febrile neutropeniaSignal | 162 | 13.1 | 11.3 | 1,799 |
| neutropeniaSignal | 279 | 11.0 | 9.8 | 2,537 |
| thrombocytopeniaSignal | 199 | 9.5 | 8.3 | 1,518 |
| disease progressionSignal | 156 | 7.1 | 6.1 | 809 |
| infectionSignal | 126 | 4.7 | 3.9 | 361 |
| anaemiaSignal | 164 | 4.6 | 4.0 | 463 |
| pneumoniaSignal | 272 | 4.5 | 4.0 | 747 |
| pyrexiaSignal | 243 | 3.8 | 3.3 | 497 |
| off label use | 269 | 1.6 | 1.5 | 70 |
| dyspnoea | 125 | 1.2 | 1.0 | 3 |
| drug ineffective | 204 | 0.8 | 0.7 | 8 |
| nausea | 112 | 0.8 | 0.6 | 9 |
| death | 116 | 0.7 | 0.6 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.